Large Cell Neuroendocrine Carcinoma of the Lung (LCNEC)
Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare and aggressive form of lung cancer that poses significant challenges in terms of diagnosis and therapy development. As a leading expert in the development of rare disease drugs and therapies, our company is dedicated to addressing unmet needs in the global pharmaceutical industry.
Overview of Large Cell Neuroendocrine Carcinoma of the Lung (LCNEC)
Large cell neuroendocrine carcinoma of the lung (LCNEC) is a subtype of non-small cell lung cancer (NSCLC) with distinct pathological and features. The incidence of LCNEC is about 1.8/100,000. LCNEC is characterized by large cells with neuroendocrine differentiation, similar to small cell lung carcinoma (SCLC), but lacks the classic SCLC cytological features. LCNEC is considered an aggressive tumor, and its prognosis is generally worse than other NSCLC subtypes.
- Pathogenesis of LCNEC
Smoking as well as certain environmental pollutants may increase the risk of LCNEC. While the role of specific genetic mutations in LCNEC is not well-defined, certain genetic alterations, such as alterations in TP53 and RB1 genes, have been observed in LCNEC tumors.
Fig.1 Distribution of LCNEC based on site of origin. (Corbett, Virginia, et al., 2021)Therapy Development for LCNEC
- Targets of LCNEC Therapy
RB1 Pathway: The Retinoblastoma 1 (RB1) gene is frequently mutated or deleted in LCNEC. Targeting this pathway may help inhibit tumor growth and improve the efficacy of therapy.
Neuroendocrine Markers: Neuroendocrine differentiation is a characteristic feature of LCNEC. Targeting neuroendocrine markers, such as chromogranin A and synaptophysin, may disrupt tumor cell function and survival.
Angiogenesis Pathway: LCNEC tumors often exhibit increased angiogenesis, promoting tumor growth and metastasis. Targeting angiogenesis pathways, such as vascular endothelial growth factor (VEGF) and its receptors, has shown promise in inhibiting tumor angiogenesis.
- Therapeutic Strategies for LCNEC
| Tumors | Experimental Arm |
|---|---|
| Rare tumors (including LCNEC) | Arm 1: nivolumab + ipilimumab. Arm 2: nivolumab |
| NSCLCs of rare histology | Atezolizumab |
| Cohort 1: SCLC; Cohort 2: Metastatic NEC of any grade/primary site (including LCNEC) |
Nivolumab + temozolomide |
| LCNEC | Durvalumab + carboplatin + etoposide × 4 → durvalumab |
| Advanced or metastatic solid tumors (including LCNEC) | Lurbinectidin every 3 weeks |
| Poorly differentiated neuroendocrine tumors, including LCNEC | Arm A: Nivolumab Arm B: nivolumab + ipilimumab |
Our Services
Our company is at the forefront of LCNEC therapy development, offering innovative solutions to address the challenges associated with this rare and aggressive disease. We provide a comprehensive range of services, including diagnostics development, therapeutics development, drug repurposing, and pre-clinical research.
Therapy Development Platforms
By continuously improving our technology platform, we aim to pool resources, knowledge, and expertise to provide pre-clinical research services with greater efficiency and quality. We offer customized animal model development services for LCNEC, allowing for the evaluation of novel therapies, including drug safety evaluation as well as pharmacokinetic analysis.
Animal Models of LCNEC
- the quadruple Rb, Rbl1, Pten, Trp53 mutant models
- Others
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Corbett, Virginia, et al. "Management of large cell neuroendocrine carcinoma." Frontiers in oncology 11 (2021): 653162.
- Andrini, Elisa, et al. "Large cell neuroendocrine carcinoma of the lung: current understanding and challenges." Journal of Clinical Medicine 11.5 (2022): 1461.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.